Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.30 |
| ▸ | PIM1 | P11309 | 2/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496266 | 0.99 | MAPT (0.38) | MAPTTHRBCRHR1GCGRNPC1 | |
| SCHEMBL6495327 | 0.86 | MAPT (0.38) | MAPTTHRBCRHR1NPC1RAB9A | |
| SCHEMBL6495627 | 0.81 | MAPT (0.45) | MAPTTHRBCRHR1NTRK1PIM1 | |
| SCHEMBL6505224 | 0.78 | CRHR1 (0.50) | MAPTTHRBCRHR1NTRK1PIM1 | |
| SCHEMBL6495922 | 0.77 | NPC1 (0.50) | MAPTCRHR1NPC1KDM4E | |
| SCHEMBL6496020 | 0.77 | MAPT (0.37) | MAPTTHRBCRHR1NPC1RAB9A | |
| SCHEMBL6496618 | 0.76 | MAPT (0.38) | MAPTTHRBCRHR1NPC1POLB | |
| SCHEMBL6504882 | 0.74 | CRHR1 (0.50) | MAPTTHRBCRHR1NPC1 | |
| SCHEMBL6495416 | 0.65 | CRHR1 (0.44) | CRHR1 | |
| SCHEMBL6497957 | 0.65 | CRHR1 (0.43) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958341-B2 | Pyrazolopyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | claimed |
| US-6958341-B2 | Pyrazolopyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| US-20030139426-A1 | Pyrazolopyrimidines as CRF antagonists | WILDE RICHARD G (US) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139426-A1 | Pyrazolopyrimidines as CRF antagonists | CRHR1, CRHR2, CRH | MAPT 2933/4885THRB 460/4885CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.